Recent News

574 News Items found
SKI immunologist Andrea Schietinger
As an autoimmune disease, Type 1 diabetes raises important questions about immune cell activity that have broad implications for immunotherapy.
Maria Jasin
In the Lab
Investigators have employed mutant mice to study how the accumulation of genetic errors is managed during egg and sperm formation.
Memorial Sloan Kettering Cancer Center research technician Matthew Solowsky
Meet Matthew Solowsky, a Navy veteran and Senior Research Technician in the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center.
Yonina Murciano-Goroff, Jenny Xue, Bob Li, Piro Lito, and Yulei Zhao.
Finding
A paper from MSK researchers reports that resistance to sotorasib, a new targeted drug for lung cancer, can be caused by many different molecular changes.
Paul Marks Prize 2021 winners
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.
By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.
Charles Rudin and Dana Pe'er
Stem-like cells that make up only a tiny fraction of the total cells in a lung tumor could be the key to stopping the disease’s deadly spread, say researchers at Memorial Sloan Kettering.
Justin Perry, PhD
Justin Perry, PhD, cell biologist and immunologist of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named a recipient of the 2021 National Institutes of Health (NIH) Director’s New Innovator Award.
Katharine Hsu and Rosa Sottile
Part natural killer, part T cell, this hybrid immune cell has a “double sword” for fighting cancer.
Dana Pe'er, PhD
Dana Pe’er, PhD, computational biologist and lab head at Memorial Sloan Kettering Cancer Center’s (MSK) Sloan Kettering Institute (SKI), is one of 33 biomedical researchers named a Howard Hughes Medical Institute (HHMI) investigator today.